Even as Eli Lilly gets underway with its next major obesity launch in Foundayo, an FDA document related to the oral treatment ...

As biosimilar competition to Johnson & Johnson’s Stelara continues to chew off sales, the much-anticipated launch of the ...

As artificial intelligence continues to rewrite the rules in countless industries, pharma companies are increasingly getting ...

Monday’s FDA approval makes Filspari the first therapy specifically indicated for FSGS, a condition that represents a $1 ...

The FDA has scolded Pfizer over Facebook ads for the cancer drug Adcetris, accusing the Big Pharma of failing to adequately ...

Despite encountering a legal roadblock last month in his effort to rework the U.S. vaccine infrastructure, HHS Secretary Robert F. Kennedy Jr. is continuing to reshape the Centers for Disease Control ...

Most biopharma brands have more approved content than ever before. Yet HCP and patient engagement haven’t kept pace. | Omnichannel isn’t a content problem. It’s an access problem. See how compliant AI ...

AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount ...

Robert F. Kennedy Jr. is starting a podcast. Unveiling the show on social media, the Department of Health and Human Services ...

Novartis is launching a three-front push to close healthcare gaps in heart disease and cancer, expanding initiatives with the ...

Fierce Biotech has released its annual ranking of the top 10 pharma R&D budgets of 2025—offering a clear look at which ...